Carbapenems and Rifampin exhibit synergy against Mycobacterium tuberculosis and Mycobacterium abscessus

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 6561-6567

  Kaushik, Amit ^a   Makkar, Nayani ^b   Pandey, Pooja ^b   Parrish, Nicole ^a   Singh, Urvashi ^b   Lamichhane, Gyanu ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BIAPENEM; CLAVULANIC ACID; DORIPENEM; ERTAPENEM; FROPENEM; IMIPENEM; ISONIAZID; MEROPENEM; PANIPENEM; RIFAMPICIN; TEBIPENEM; BETA LACTAM; CARBAPENEM DERIVATIVE; THIENAMYCIN DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG HYDROLYSIS; DRUG POTENTIATION; GROWTH INHIBITION; INHIBITORY CONCENTRATION; MIC90; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOPHILICITY; PRIORITY JOURNAL; TUBERCULOSIS; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MYCOBACTERIUM;

ANTITUBERCULAR AGENTS; BETA-LACTAMS; CARBAPENEMS; DRUG SYNERGISM; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; THIENAMYCINS;

EID: 84942883130     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01158-15     Document Type: Article

References (34)

1. Flores AR, Parsons LM, Pavelka MS, Jr. 2005. Genetic analysis of the beta-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to beta-lactam antibiotics. Microbiology 151:521-532. http://dx.doi.org/10.1099/mic.0.27629-0.
2. Hugonnet JE, Blanchard JS. 2007. Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. Biochemistry 46: 11998-12004. http://dx.doi.org/10.1021/bi701506h.
3. Tremblay LW, Hugonnet JE, Blanchard JS. 2008. Structure of the covalent adduct formed between Mycobacterium tuberculosis beta-lactamase and clavulanate. Biochemistry 47:5312-5316. http://dx.doi.org/10.1021/bi8001055.
4. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. 2011. Carbapenems: past, present, and future. Antimicrob Agents Chemother 55:4943-4960. http://dx.doi.org/10.1128/AAC.00296-11.
5. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE, III, Blanchard JS. 2009. Meropenem-clavulanate is effective against extensively drugresistant Mycobacterium tuberculosis. Science 323:1215-1218. http://dx.doi.org/10.1126/science.1167498.
6. Kumar P, Arora K, Lloyd JR, Lee IY, Nair V, Fischer E, Boshoff HI, Barry CE, III. 2012. Meropenem inhibits D,D-carboxypeptidase activity in Mycobacterium tuberculosis. Mol Microbiol 86:367-381. http://dx.doi.org/10.1111/j.1365-2958.2012.08199.x.
7. Solapure S, Dinesh N, Shandil R, Ramachandran V, Sharma S, Bhattacharjee D, Ganguly S, Reddy J, Ahuja V, Panduga V, Parab M, Vishwas KG, Kumar N, Balganesh M, Balasubramanian V. 2013. In vitro and in vivo efficacy of beta-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 57:2506-2510. http://dx.doi.org/10.1128/AAC.00023-13.
8. Gonzalo X, Drobniewski F. 2013. Is there a place for beta-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate. J Antimicrob Chemother 68:366-369.
9. Horita Y, Maeda S, Kazumi Y, Doi N. 2014. In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with beta-lactamase inhibitors. Antimicrob Agents Chemother 58:7010-7014. http://dx.doi.org/10.1128/AAC.03539-14.
10. Olivier KN, Weber DJ, Wallace RJ, Jr, Faiz AR, Lee JH, Zhang Y, Brown-Elliot BA, Handler A, Wilson RW, Schechter MS, Edwards LJ, Chakraborti S, Knowles MR, Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. 2003. Nontuberculous mycobacteria. I. Multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 167:828-834.
11. Soroka D, Dubee V, Soulier-Escrihuela O, Cuinet G, Hugonnet JE, Gutmann L, Mainardi JL, Arthur M. 2014. Characterization of broadspectrum Mycobacterium abscessus class A beta-lactamase. J Antimicrob Chemother 69:691-696. http://dx.doi.org/10.1093/jac/dkt410.
12. Gavan TL, Town MA. 1970. A microdilution method for antibiotic susceptibility testing: an evaluation. Am J Clin Pathol 53:880-885.
13. Cynamon MH, Speirs RJ, Welch JT. 1998. In vitro antimycobacterial activity of 5-chloropyrazinamide. Antimicrob Agents Chemother 42:462-463.
14. Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of mycobacteria, nocardiae and other aerobic actinomycetes. Approved standard M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Hsieh MH, Yu CM, Yu VL, Chow JW. 1993. Synergy assessed by checkerboard. A critical analysis. Diagn Microbiol Infect Dis 16:343-349. http://dx.doi.org/10.1016/0732-8893(93)90087-N.
16. Takeuchi Y, Sunagawa M, Isobe Y, Hamazume Y, Noguchi T. 1995. Stability of a 1 beta-methylcarbapenem antibiotic, meropenem (SM-7338) in aqueous solution. Chem Pharm Bull 43:689-692. http://dx.doi.org/10.1248/cpb.43.689.
17. Walsh C. 2003. Antibiotics: actions, origins, resistance. ASM Press, Washington, DC.
18. Wivagg CN, Bhattacharyya RP, Hung DT. 2014. Mechanisms of betalactam killing and resistance in the context of Mycobacterium tuberculosis. J Antibiot 67:645-654. http://dx.doi.org/10.1038/ja.2014.94.
19. Schoonmaker MK, Bishai WR, Lamichhane G. 2014. Nonclassical transpeptidases of Mycobacterium tuberculosis alter cell size, morphology, the cytosolic matrix, protein localization, virulence, and resistance to betalactams. J Bacteriol 196:1394-1402. http://dx.doi.org/10.1128/JB.01396-13.
20. Lavollay M, Arthur M, Fourgeaud M, Dubost L, Marie A, Veziris N, Blanot D, Gutmann L, Mainardi JL. 2008. The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains crosslinks generated by L,D-transpeptidation. J Bacteriol 190:4360-4366. http://dx.doi.org/10.1128/JB.00239-08.
21. Dubee V, Triboulet S, Mainardi JL, Etheve-Quelquejeu M, Gutmann L, Marie A, Dubost L, Hugonnet JE, Arthur M. 2012. Inactivation of Mycobacterium tuberculosis L,D-transpeptidase LdtMt(1) by carbapenems and cephalosporins. Antimicrob Agents Chemother 56:4189-4195. http://dx.doi.org/10.1128/AAC.00665-12.
22. Erdemli SB, Gupta R, Bishai WR, Lamichhane G, Amzel LM, Bianchet MA. 2012. Targeting the cell wall of Mycobacterium tuberculosis: structure and mechanism of L,D-transpeptidase 2. Structure 20:2103-2115. http://dx.doi.org/10.1016/j.str.2012.09.016.
23. Kim HS, Kim J, Im HN, Yoon JY, An DR, Yoon HJ, Kim JY, Min HK, Kim SJ, Lee JY, Han BW, Suh SW. 2013. Structural basis for the inhibition of Mycobacterium tuberculosis L,D-transpeptidase by meropenem, a drug effective against extensively drug-resistant strains. Acta CrystallogrDBiol Crystallogr 69:420-431. http://dx.doi.org/10.1107/S0907444912048998.
24. Correale S, Ruggiero A, Capparelli R, Pedone E, Berisio R. 2013. Structures of free and inhibited forms of the L,D-transpeptidase LdtMt1 from Mycobacterium tuberculosis. Acta Crystallogr D Biol Crystallogr 69:1697-1706. http://dx.doi.org/10.1107/S0907444913013085.
25. Li WJ, Li DF, Hu YL, Zhang XE, Bi LJ, Wang DC. 2013. Crystal structure of L,D-transpeptidase LdtMt2 in complex with meropenem reveals the mechanism of carbapenem against Mycobacterium tuberculosis. Cell Res 23:728-731. http://dx.doi.org/10.1038/cr.2013.53.
26. Cordillot M, Dubee V, Triboulet S, Dubost L, Marie A, Hugonnet JE, Arthur M, Mainardi JL. 2013. In vitro cross-linking of peptidoglycan by Mycobacterium tuberculosis L,D-transpeptidases and inactivation of these enzymes by carbapenems. Antimicrob Agents Chemother 57:5940-5945. http://dx.doi.org/10.1128/AAC.01663-13.
27. Tremblay LW, Fan F, Blanchard JS. 2010. Biochemical and structural characterization of Mycobacterium tuberculosis beta-lactamase with the carbapenems ertapenem and doripenem. Biochemistry 49:3766-3773. http://dx.doi.org/10.1021/bi100232q.
28. Kurz SG, Wolff KA, Hazra S, Bethel CR, Hujer AM, Smith KM, Xu Y, Tremblay LW, Blanchard JS, Nguyen L, Bonomo RA. 2013. Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis betalactamase BlaC lead to clavulanate resistance?: a biochemical rationale for the use of beta-lactam-beta-lactamase inhibitor combinations. Antimicrob Agents Chemother 57:6085-6096. http://dx.doi.org/10.1128/AAC .01253-13.
29. Chow C, Xu H, Blanchard JS. 2013. Kinetic characterization of hydrolysis of nitrocefin, cefoxitin, and meropenem by beta-lactamase from Mycobacterium tuberculosis. Biochemistry 52:4097-4104. http://dx.doi.org/10.1021/bi400177y.
30. Hazra S, Xu H, Blanchard JS. 2014. Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the beta-lactamase from Mycobacterium tuberculosis. Biochemistry 53:3671-3678. http://dx.doi.org/10.1021/bi500339j.
31. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, Matter L, Schopfer K, Bodmer T. 1993. Detection of rifampicinresistance mutations in Mycobacterium tuberculosis. Lancet 341:647-650. http://dx.doi.org/10.1016/0140-6736(93)90417-F.
32. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, Darst SA. 2001. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104:901-912. http://dx.doi.org/10.1016/S0092-8674(01)00286-0.
33. Lavollay M, Dubee V, Heym B, Herrmann JL, Gaillard JL, Gutmann L, Arthur M, Mainardi JL. 2014. In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex. Clin Microbiol Infect 20: O297-O300. http://dx.doi.org/10.1111/1469-0691.12405.
34. Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. 2012. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother 67:810-818. http://dx.doi.org/10.1093/jac/dkr578.